MyoKardia's Mavacamten 'Impressive' In Hypertrophic Cardiomyopathy
Launch Planning Underway For The Biotech's Lead Candidate
MyoKardia is building up its organization to prepare for commercialization of mavacamten, a potential first-in-class agent for obstructive hypertrophic cardiomyopathy.
